In Parkinson’s disease (PD) dopamine (DA) neurons located in the substantia nigra (SN) degenerate and die. Since all current therapies only treat symptoms, we hope to develop novel disease-modifying ...

Researchers have discovered a novel neurotrophic factor CDNF (Conserved Dopamine Neurotrophic Factor) that was shown to protect and even rescue damaged dopamine neurons in an experimental model of ...

Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson`s disease and potentially other ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

Figure: Solution structure of human MANF protein. PDB ID: 2KVD [7]. Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte derived neurotrophic factor (MANF) form an evolutionary ...

Herantis Pharma`s clinical study with CDNF in Parkinson`s disease authorized in Sweden Herantis Pharma Plc Company release 23 March 2017 at 12:30 pm The Medicines Agency of Sweden, MPA, has authorized ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

Nanoform (Finland), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (Finland), focusing on disease modifying therapies for debilitating neurodegenerative diseases based ...

With a horrific mortality and recovery rate, intracerebral hemorrhage (ICH) is a devastating disease with poor long-term outcomes for those who do manage to survive it. And studies show that for ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...